Dr. Gilbert on the Safety Profile of Mirvetuximab Soravtansine/Bevacizumab in Ovarian Cancer
Lucy Gilbert, MD, MSc, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.
Lucy Gilbert, MD, MSc, professor, departments of obstetrics and gynecology, and oncology, McGill University, director, Gynecologic Oncology and Women’s Health Research Unit, McGill University Health Center, discusses the safety profile of mirvetuximab soravtansine in combination with bevacizumab (Avastin) in patients with platinum-agnostic ovarian cancer.
A study presented at the 2020 ASCO Virtual Scientific Program did not show new or unexpected adverse effects (AEs) with the combination versus the known safety profile of each agent alone, says Gilbert.
The majority of patients had low-grade AEs, which were typically gastrointestinal or ocular in nature, said Gilbert. Ocular toxicities were generally well managed with local strategies, such as steroid eyedrops.
Grade 3 or greater hypertension occurred in 12% of patients, explains Gilbert. Additionally, 10% of patients had grade 3 or greater myelosuppression or neutropenia. Comparatively, single-agent chemotherapy elicits higher rates of neutropenia in the recurrent setting, Gilbert concludes.
